1st February 2018


A survey of the first UK patients to use Soratinex, a treatment for psoriasis that does not contain potentially-harmful steroids, has found that almost three-quarters enjoyed ‘excellent’ or ‘good’ results.

The three-part treatment, a gel, oil and cream, was launched in Britain last October following clinical trials in London in which six out of 10 patients enjoyed improvements in their symptoms of between 51 and 100 per cent.

The patient satisfaction survey, conducted by FRANKL Pharma, European distributors of Soratinex, went out to the first 1,000 patients to complete an eight-week course of the treatment. Of the first 100 to reply, 49 per cent described their results as ‘Excellent’ with a further 24 per cent enjoying ‘Good’ improvements.

The survey asked patients to sum up their experience of Soratinex in one word of their choosing and 40 per cent answered ‘Amazing’, ‘Miraculous’, ‘Excellent’ or ‘Great’.

Significantly, when asked whether they would prefer to use steroid or non-steroid treatments, more than 92 per cent said they preferred non-steroid.

Psoriasis is an immune condition that speeds up the skin replacement process, meaning cells that normally take 21 to 28 days to replace are actually produced in a few days. This build-up of cells results in raised ‘plaques’ which can become inflamed, flaky and painful . It can occur on all parts of the body. Almost 2 million people in the UK suffer from the condition.

Most sufferers are treated with topical creams containing steroids. However, over time these can damage the skin and in some cases are absorbed into the body, causing side effects such as changes in blood pressure and decreased growth in children.